BiomX Reports First Quarter 2024 Financial Results and Provi

Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025 Company will host a...

Related Keywords

Israel , United States , American , Israeli , Jonathan Solomon , Assaf Oron , Exchange Commission , Global Congress , European Society Of Clinical Microbiology , Clinical Program Updates , Drug Administration , Israeli Innovation Authority , Biomx Inc , Cystic Fibrosis Foundation , Action Fund , Participant International Dial , Adaptive Phage Therapeutics Inc , Adaptive Phage Therapeutics , Chief Executive Officer , Top Poster , Deerfield Management , Nantahala Capital , Orphan Drug Designation , United States Food , European Society , Clinical Microbiology , Infectious Diseases , Foot Osteomyelitis , Call Dial In Information , Dial In Number , Orphan Drug , Ophage Lead , Securities Litigation Reform Act , Annual Report , Capital Deficiency , Private Placement , Common Stock ,